This post hoc analysis of a randomized phase 3 trial (NCT05515471) assessed the efficacy of perfluorohexyloctane in treating dry eye disease (DED) associated with meibomian gland dysfunction (MGD) based on baseline disease severity. Participants were categorized by baseline severity using total corneal fluorescein staining (tCFS), tear film breakup time, MGD score, eye dryness scores (EDS), and ocular surface disease index score. The primary outcomes were response rates at day 57 for tCFS, EDS, and combined tCFS and EDS. Results indicated that perfluorohexyloctane significantly improved EDS (OR: 2.25; 95% CI: 1.34, 3.80), tCFS (OR: 2.21; 95% CI: 1.38, 3.55), and combined tCFS and EDS (OR: 2.56; 95% CI: 1.62, 4.04) compared to 0.6% sodium chloride. A significant interaction was noted for baseline tCFS score on EDS response, with a greater effect in participants with tCFS ≥6 (propensity score-weighted OR: 4.35) compared to those with tCFS <6 (OR: 1.26; P = 0.0317). Safety and tolerability were consistent across different baseline severities. The study concludes that perfluorohexyloctane is effective and well-tolerated in improving DED symptoms associated with MGD.
AI Accuracy Review: 9/10
· Auto-published
If you suffer from dry eye disease, you know how frustrating it can be. New eye drops made from perfluorohexyloctane have shown encouraging results in helping patients feel better. In a study, those using these drops had greater chances of seeing improvements in their eye dryness and overall eye health compared to those using a saline solution. This was especially true for patients with more severe symptoms. For those with higher baseline scores for corneal staining, the drops made a significant difference in their comfort levels. Importantly, these eye drops were well tolerated, meaning most people didn’t experience negative side effects. This could be a game-changer for many who are looking for effective relief from dry eye disease associated with meibomian gland dysfunction.
What this means for you: New eye drops improved dry eye symptoms, especially for those with more severe conditions.
View Original Abstract ↓
PURPOSE: This post hoc analysis aimed to explore the effect of perfluorohexyloctane on dry eye disease (DED) associated with meibomian gland dysfunction (MGD) by baseline disease severity.
METHODS: Data from a randomized phase 3 trial (NCT05515471) were divided based on the baseline severity of DED signs (total corneal fluorescein staining [tCFS] score: < 6 or ≥ 6; tear film breakup time: < 3 or ≥ 3; MGD score: < 7 or ≥ 7) or symptoms (eye dryness scores [EDS]: < 70 or ≥ 70; ocular surface disease index score: < 60 or ≥ 60). The main outcomes of interest included response rates at day 57 of tCFS score, EDS, and tCFS and EDS, safety, and tolerability.
RESULTS: Participants treated with perfluorohexyloctane had greater odds of achieving EDS (odds ratio [OR]: 2.25; 95% confidence interval [CI]: 1.34, 3.80), tCFS (OR: 2.21; 95% CI: 1.38, 3.55), and tCFS and EDS (OR: 2.56; 95% CI: 1.62, 4.04) responses than those treated with 0.6% sodium chloride in the overall population. No significant treatment interaction effect was observed by any DED signs or symptoms except for a significant effect of baseline tCFS score on EDS response, with a relatively large effect in participants with tCFS ≥ 6 versus tCFS < 6 (propensity score-weighted OR: 4.35 versus 1.26; P = 0.0317). The safety and tolerability profiles of perfluorohexyloctane stratified by baseline disease severity were generally consistent.
CONCLUSION: Perfluorohexyloctane was well tolerated and improved the signs and symptoms of DED associated with MGD in patients with different baseline disease severity compared to saline control.
